Table e-1. Distribution of patients at each value of 90-day mRS among two study groups

mRS	Aspirin (n=2569)	Clopidogrel and Aspirin (n=2562)
0	1573	1551
1	697	757
2	102	94
3	50	43
4	122	92
5	15	15
6	10	10

Table e-2. Demographic and clinical characteristics between two study groups in no-stroke population

Characteristics	Overall (N=4616)	Aspirin (N=2266)	Clopidogrel and Aspirin (N=2350)	P value
Age, median (IQR), year	62.1 (54.6-71.1)	61.8 (54.2-70.8)	62.5 (54.9-71.5)	0.04
Female, n (%)	1543 (33.4)	779 (34.4%)	764 (32.5)	0.18
Systolic BP >140 mmHg, n (%)	3352 (72.7)	1633 (72.1)	1719 (73.2)	0.40
Diastolic BP >90 mmHg, n (%)	2405 (52.1)	1178 (52.0)	1227 (52.2)	0.88
Medical history				
Stroke or TIA, n (%)	1053 (22.8)	511 (22.6)	542 (23.1)	0.68
Hypertension, n (%)	2999 (65.0)	1454 (64.2)	1545 (65.7)	0.26
Dyslipidemia, n (%)	510 (11.0)	254 (11.2)	256 (10.9)	0.73
Coronary heart disease, n (%)	237 (5.1)	118 (5.2)	119 (5.1)	0.83
Known atrial fibrillation or flutter, n (%)	156 (3.4)	73 (3.2)	83 (3.5)	0.56

Current or previous smoking, n (%)	1996 (43.2)	968 (42.7)	1028 (43.7)	0.48
Heavy alcohol, n (%)	1431 (31.0)	696 (30.7)	735 (31.3)	0.68
BMI at admission, median (IQR), kg/m^2	24.5 (22.7-26.4)	24.5 (22.9-26.5)	24.4 (22.6-26.3)	0.06
Time to randomization (< 12 hours), n (%)	2268 (49.1)	1109 (48.9)	1159 (49.3)	0.80
NIHSS score at baseline, median (IQR)	1 (0-2)	1 (0-2)	1 (0-2)	0.32
mRS score before the onset of index events				0.60
0	3806 (82.5)	1880 (83.0)	1926 (82.0)	
1	689 (14.9)	326 (14.4)	363 (15.4)	
2	121 (2.6)	60 (2.6)	61 (2.6)	
Qualifying events				0.75
Minor stroke, n (%)	3314 (71.8)	1622 (71.6)	1692 (72.0)	
High-risk TIA, n (%)	1302 (28.2)	644 (28.4)	658 (28.0)	

TIA denotes Transient Ischemic Attack; IQR, Interquartile Range; BP, Blood Pressure; BMI, Body Mass Index; NIHSS, National Institutes of Health Stroke Scale;

mRS, Modified Rankin Scale;

**Table e-3.   Demographic and clinical characteristics between two study groups in stroke population**

Characteristics	Overall (N=515)	Aspirin (N=303)	Clopidogrel and Aspirin (N=212)	P value
Age, median (IQR), year	63.8 (56.0-73.0)	63.6 (56.0-73.4)	64.1 (55.9-71.9)	0.70
Female, n (%)	195 (37.9)	113 (37.3)	82 (38.7)	0.75
Systolic BP >140 mmHg, n (%)	415 (80.7)	250 (82.5)	165 (78.2)	0.22
Diastolic BP >90 mmHg, n (%)	290 (56.3)	182 (60.1)	108 (50.9)	0.04
Medical history				
Stroke or TIA, n (%)	113 (21.9)	65 (21.5)	48 (22.6)	0.75
Hypertension, n (%)	378 (73.4)	220 (72.6)	158 (74.5)	0.63
Dyslipidemia, n (%)	56 (10.9)	26 (8.6)	30 (14.2)	0.05
Coronary heart disease, n (%)	20 (3.9)	14 (4.6)	6 (2.8)	0.30
Known atrial fibrillation or flutter, n (%)	19 (3.7)	14 (4.6)	5 (2.4)	0.18

Current or previous smoking, n (%)	204 (39.6)	129 (42.6)	75 (35.4)	0.10
Heavy alcohol, n (%)	157 (30.5)	97 (32.0)	60 (28.3)	0.37
BMI at admission, median (IQR), kg/m2	25.0 (22.9-26.7)	24.9 (22.8-26.7)	25.1 (23.0-26.8)	0.58
Time to randomization (< 12 hours), n (%)	287 (55.7)	162 (53.5)	125 (59.0)	0.22
NIHSS score at baseline, median (IQR)	2 (1-3)	2 (1-3)	2 (1-3)	0.04
mRS score before the onset of index events				0.86
0	427 (82.9)	253 (83.5)	174 (82.1)	
1	71 (13.8)	41 (13.5)	30 (14.2)	
2	17 (3.3)	9 (3.0)	8 (3.8)	
Qualifying events				0.72
Minor stroke, n (%)	382 (74.2)	223 (73.6)	159 (75.0)	
High-risk TIA, n (%)	133 (25.8)	80 (26.4)	53 (25.0)	

TIA denotes Transient Ischemic Attack; IQR, Interquartile Range; BP, Blood Pressure; BMI, Body Mass Index; NIHSS, National Institutes of Health Stroke Scale;

mRS, Modified Rankin Scale;

Figure e-1. Percentage distribution of response to the EQ-5D questionnaire among

two study groups at 90-day follow-up

EQ-5D, EuroQol-5 Dimensions; A, Aspirin; C, Clopidogrel.